Get the Stockscreener App
1.72
0.57%
-0.01
Nautilus Biotechnology Inc stock is traded at $1.72, with a volume of 515.37K.
It is down -0.57% in the last 24 hours and down -28.03% over the past month.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
See More
Previous Close:
$1.73
Open:
$1.75
24h Volume:
515.37K
Relative Volume:
0.94
Market Cap:
$218.58M
Revenue:
-
Net Income/Loss:
$-57.09M
P/E Ratio:
-3.8078
EPS:
-0.4517
Net Cash Flow:
$-51.43M
1W Performance:
-3.91%
1M Performance:
-28.03%
6M Performance:
-8.02%
1Y Performance:
+109.77%
1-Day Range:
$1.67
$1.755
1-Week Range:
$1.67
$1.995
52-Week Range:
$0.62
$4.3101
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
Name
Nautilus Biotechnology Inc
Sector
Industry
Phone
206-333-2001
Address
2701 EASTLAKE AVE EAST, SEATTLE
Compare NAUT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAUT
Nautilus Biotechnology Inc
|
1.72 | 237.64M | 0 | -57.09M | -51.43M | -0.4517 |
VRTX
Vertex Pharmaceuticals Inc
|
528.23 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
647.45 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
926.34 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.78 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.28 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Downgrade | Goldman | Neutral → Sell |
| Jun-27-24 | Initiated | Guggenheim | Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-02-21 | Initiated | Cowen | Outperform |
| Aug-04-21 | Initiated | Goldman | Neutral |
| Jul-13-21 | Initiated | Jefferies | Buy |
View All
Nautilus Biotechnology Inc Stock (NAUT) Latest News
Form 13D/A Nautilus Biotechnology For: 30 June By Investing.com - Investing.com Canada
Andreessen Horowitz trims Nautilus (NAUT) stake in June 2026 block trade - Stock Titan
Nautilus Biotechnology, Inc.(NasdaqCM:NAUT) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Nautilus Biotechnology, Inc.(NasdaqCM: NAUT) added to Russell 2500 Growth Benchmark - marketscreener.com
Nautilus Biotechnology, Inc.(NasdaqCM: NAUT) added to Russell 2000 Index - marketscreener.com
Nautilus Biotechnology, Inc.(NasdaqCM: NAUT) added to Russell 2000 Value Benchmark - marketscreener.com
Nautilus Biotechnology, Inc.(NasdaqCM:NAUT) added to Russell Microcap Value Benchmark Index - marketscreener.com
Nautilus Biotechnology, Inc.(NasdaqCM:NAUT) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Nautilus Biotechnology, Inc.(NasdaqCM: NAUT) added to Russell 2000 Growth Benchmark - marketscreener.com
Nautilus Biotechnology, Inc.(NasdaqCM: NAUT) added to Russell 3000E Growth Benchmark - marketscreener.com
Nautilus Biotechnology, Inc.(NasdaqCM: NAUT) added to Russell Microcap Index - marketscreener.com
Nautilus Biotechnology Inc (NAUT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Nautilus Biotechnolgy, Inc. Actuals & Estimates (NASDAQ:NAUT) - TradingView
NAUTILUS BIOTECHNOLOGY INC (NAUT) Stock Chart - ChartMill
NAUT Forecast — Price Target — Prediction for 2027 - TradingView
Press Release: Nautilus Biotechnology Reports First Quarter 2026 Financial Results - Moomoo
[Form 4] Nautilus Biotechnology, Inc. Insider Trading Activity - Stock Titan
Director at Nautilus (NAUT) granted 45,000 stock options vesting monthly - Stock Titan
Nautilus Biotechnology (NAUT) grants 45,000 stock options to director - Stock Titan
Nautilus Biotech stockholders approve directors and governance items - TipRanks
Nautilus Biotechnology (NAUT) investors approve directors, auditor and annual Say on Pay - Stock Titan
NAUT News | NAUTILUS BIOTECHNOLOGY INC (NASDAQ:NAUT) - ChartMill
Nautilus Biotechnology Inc (NAUT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nautilus Biotechnology Inc (NAUT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Nautilus Biotechnology Inc (NAUT) Institutional Confidence - TradingKey
Nautilus Biotechnology Inc (NAUT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Nautilus Biotechnology Inc (NAUT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nautilus Biotechnology Inc (NAUT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nautilus Biotechnology Inc (NAUT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nautilus Biotechnology Inc (NAUT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nautilus Biotechnology (NAUT) Slides 2.67% as Shares Test Key Support ZoneETF AUM Growth - newsline.com
Nautilus Biotechnology (NAUT) Holds Near Support After Modest UptickETF Outflow Streak - newsline.com
Nautilus Biotechnology (NAUT) Shows Modest Gains Amid Tight Trading RangeNaked POC - newsline.com
Nautilus Biotechnology (NAUT) Edges Higher Amid Biotech Sector Gains; Resistance Test in FocusForce Index - newsline.com
Nautilus Biotechnology (NAUT) Plunges 10.8% as Bearish Momentum BuildsLow Risk Entry Stocks - newsline.com
Tau proteoform quantification research unveiled by Nautilus Biotechnology at ASMS2026 - Traders Union
Andreessen Horowitz (NAUT) funds sell 5M shares, retain near-10% stake - Stock Titan
Andreessen Horowitz funds trim Nautilus (NAUT) stake with 5M-share open-market sale - Stock Titan
Nautilus Biotechnology promotes single molecule proteomics at ASMS with Voyager platform experts - Traders Union
3 Penny Stocks With Market Caps Over $100M To Watch - simplywall.st
Nautilus Biotechnology (NAUT) Surges 5.4% as Biotech Sector Momentum BuildsIntraday Profile - The Legal Advocate
Nautilus Biotechnology (NAUT) Surges Over 5% as Small-Cap Biotech Shows Renewed StrengthMoney Flow - newsline.com
NAUT Q1 2026 Earnings: Narrowed Losses Beat Estimates Amid Platform ProgressEPS Miss Report - The Legal Advocate
Nautilus Biotechnology (NAUT) Pulls Back: Key Levels to Watch After 3.9% DeclineEnding Diagonal - The Legal Advocate
NAUTNautilus Biotechnology Inc Stock Price and Quote - Finviz
Nautilus Biotechnology (NAUT) Holds Steady at $2.54 as Stock Consolidates Near Key LevelsLow Volatility Picks - Newser
NAUT Stock Price, Quote & Chart | NAUTILUS BIOTECHNOLOGY INC (NASDAQ:NAUT) - ChartMill
Nautilus Biotechnology (NAUT) Q1 2026 Earnings Surprise: EPS $-0.12, Up SignificantStock Analysis Community - Newser
Nautilus Biotechnology Decline Means Insider Profits Down To US$432k - Moomoo
Nautilus Biotechnology introduces Voyager Platform for precise tau proteoform analysis - Traders Union
TradingKey - TradingKey
Nautilus Biotechnology Inc Stock (NAUT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nautilus Biotechnology Inc Stock (NAUT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Patel Sujal M | CEO, President, and Secretary |
Mar 04 '26 |
Buy |
2.61 |
25,000 |
65,238 |
10,366,721 |
| Suzuki Kentaro | Chief Marketing Officer |
Nov 06 '25 |
Buy |
1.49 |
4,000 |
5,960 |
4,000 |
| Patel Sujal M | CEO, President, and Secretary |
Sep 05 '25 |
Buy |
0.67 |
116,500 |
78,544 |
10,258,221 |
| Patel Sujal M | CEO, President, and Secretary |
Sep 08 '25 |
Buy |
0.68 |
83,500 |
57,031 |
10,341,721 |
| Murphy Matthew B. | General Counsel |
Sep 04 '25 |
Buy |
0.64 |
20,000 |
12,858 |
74,140 |
0.72%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):